Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DDX3X | O00571 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240105 | 0.97 | ADRB3 (0.35) | ADRB3LMNASMN1; SMN2ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL4638592 | 0.91 | ADRB3 (0.37) | ADRB3ADRB2ADRB1HTR6MAPT | |
| Trifluoroacetic Acid SCHEMBL2948615 | 0.90 | SMN1; SMN2 (0.40) | ADRB3LMNASMN1; SMN2ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL2941086 | 0.88 | ADRB3 (0.39) | ADRB3ADRB2ADRB1HTR6NTSR1 | |
| Trifluoroacetic Acid SCHEMBL28775802 | 0.88 | ADRB3 (0.39) | ADRB3ADRB2ADRB1HTR6NTSR1 | |
| SCHEMBL13240065 | 0.86 | SMN1; SMN2 (0.42) | ADRB3LMNASMN1; SMN2ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL2943684 | 0.86 | ADRB3 (0.39) | ADRB3SMN1; SMN2HTR6MAPT | |
| Trifluoroacetic Acid SCHEMBL27739497 | 0.86 | ADRB3 (0.39) | ADRB3SMN1; SMN2HTR6MAPT | |
| Trifluoroacetic Acid SCHEMBL2953642 | 0.86 | ADRB3 (0.37) | ADRB3LMNAADRB2ADRB1HTR6 | |
| Trifluoroacetic Acid SCHEMBL27739597 | 0.86 | ADRB3 (0.37) | ADRB3LMNAADRB2ADRB1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885LMNA 816/4885SMN1; SMN2 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.